Clinical Trial Update: Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 safety, efficacy, and tolerability study of ASP3291 in active ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ASP3291

Snippet

Sponsor: Telsar Pharma Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED